Lv1
50 积分 2025-04-11 加入
Once-Weekly Semaglutide in Adults with Overweight or Obesity
11小时前
待确认
Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic Disorders
18小时前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
8天前
已完结
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
8天前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
9天前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
13天前
已完结
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
14天前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
16天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
16天前
已完结
Novel Options in Metastatic and Non-surgically Curable Bladder Cancer
1个月前
已完结
皖公网安备34019202002308
